文献速递浆细胞疾病造血干细胞移植与细胞治疗

单克隆免疫球蛋白促进多发性骨髓瘤的骨丢失

Monoclonal immunoglobulins promote bone loss in multiple myeloma.
PubMed 文献 · Blood · 2020-01-01

本研究探讨多发性骨髓瘤患者免疫球蛋白糖基化与骨病的关系。体外实验显示,骨病患者的免疫球蛋白可促进人前破骨细胞向破骨细胞分化,而无骨病患者的免疫球蛋白无此作用;骨病患者IgG半乳糖化水平显著低于无骨病患者,唾液酸化水平低于健康人,且骨病发作时血清IgG唾液酸化显著降低。5TGM1小鼠模型中,唾液酸前体N-乙酰甘露糖胺(ManNAc)治疗减少病灶数并降低破骨细胞活性标志物CTX-1水平,同时增加IgG-Fc唾液酸化。

要点

  • 骨病多发性骨髓瘤患者的免疫球蛋白体外促进人前破骨细胞分化,无骨病患者者不促进。
  • 骨病患者IgG半乳糖化显著低于无骨病患者,唾液酸化低于健康人。
  • 5TGM1小鼠中ManNAc治疗减少病灶数和CTX-1水平,并增加IgG-Fc唾液酸化。

核心结论

  • 去糖基化免疫球蛋白促进多发性骨髓瘤骨丢失,改变IgG糖基化可能是减少骨丢失的治疗策略。

研究设计与样本

  • 体外研究:将多发性骨髓瘤患者分离的免疫球蛋白加入人前破骨细胞;比较骨病患者与无骨病患者免疫球蛋白的效应。
  • 糖基化分析:比较骨病患者与无骨病患者IgG半乳糖化,以及患者与健康人IgG唾液酸化。
  • 动物实验:5TGM1小鼠骨髓瘤模型,给予唾液酸前体N-乙酰甘露糖胺(ManNAc)治疗,观察病灶数和CTX-1水平。

主要发现

  • 骨病患者免疫球蛋白在体外促进人前破骨细胞分化,无骨病患者免疫球蛋白不促进;效应主要由免疫复合物或聚集体介导。
  • 骨病患者IgG半乳糖化显著低于无骨病患者;骨病患者IgG唾液酸化显著低于健康人。
  • 骨病发作时患者血清IgG唾液酸化显著降低。
  • 5TGM1小鼠中,ManNAc治疗组病灶数减少、CTX-1水平降低,且IgG-Fc唾液酸化增加。

临床怎么用

  • 原文结论支持改变IgG糖基化可能是减少多发性骨髓瘤骨丢失的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with multiple myeloma develop a severe osteolytic bone disease. The myeloma cells secrete immunoglobulins, and the presence of monoclonal immunoglobulins in the patient's sera is an important diagnostic criterion. Here, we show that immunoglobulins isolated from myeloma patients with bone disease promote osteoclast differentiation when added to human preosteoclasts in vitro, whereas immunoglobulins from patients without bone disease do not. This effect was primarily mediated by immune complexes or aggregates. The function and aggregation behavior of immunoglobulins are partly determined by differential glycosylation of the immunoglobulin-Fc part. Glycosylation analyses revealed that patients with bone disease had significantly less galactose on immunoglobulin G (IgG) compared with patients without bone disease and also less sialic acid on IgG compared with healthy persons. Importantly, we also observed a significant reduction of IgG sialylation in serum of patients upon onset of bone disease. In the 5TGM1 mouse myeloma model, we found decreased numbers of lesions and decreased CTX-1 levels, a marker for osteoclast activity, in mice treated with a sialic acid precursor, N-acetylmannosamine (ManNAc). ManNAc treatment increased IgG-Fc sialylation in the mice. Our data support that deglycosylated immunoglobulins promote bone loss in multiple myeloma and that altering IgG glycosylation may be a therapeutic strategy to reduce bone loss.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Westhrin M, Kovcic V, Zhang Z, et al. Monoclonal immunoglobulins promote bone loss in multiple myeloma. Blood. 2020. PMID: 32575115. doi:10.1182/blood.2020006045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。